natgillin/translations-raw huggingface dataset:
Advagraf 1 mg prolonged-release hard capsules
Advagraf 1 mg trde kapsule s podaljšanim sproščanjem
Advagraf 1 mg prolonged-release hard capsules Tacrolimus
Advagraf 1 mg trde kapsule s podaljšanim sproščanjem takrolimus
Advagraf 3 mg prolonged-release hard capsules
Advagraf 3 mg trde kapsule s podaljšanim sproščanjem
Advagraf 3 mg prolonged-release hard capsules Tacrolimus
Advagraf 3 mg trde kapsule s podaljšanim sproščanjem takrolimus
Advagraf 5 mg prolonged-release hard capsules
Advagraf 5 mg trde kapsule s podaljšanim sproščanjem
Advagraf 5 mg prolonged-release hard capsules Tacrolimus
Advagraf 5 mg trde kapsule s podaljšanim sproščanjem takrolimus
Advagraf contains lactose (milk sugar).
Zdravilo Advagraf vsebuje laktozo (mlečni sladkor).
Advagraf contains lactose and lecithin (soya)
Zdravilo Advagraf vsebuje laktozo in lecitin (soja)
Advagraf contains the active substance tacrolimus.
Zdravilo Advagraf vsebuje zdravilno učinkovino takrolimus.
Advagraf is a once-a-day oral formulation of tacrolimus.
Zdravilo Advagraf je peroralna farmacevtska oblika takrolimusa, ki se jemlje enkrat na dan.
Advagraf is used to control your body’s immune response, enabling your body to accept the transplanted organ.
Zdravilo Advagraf uporabljamo za obvladovanje telesnega imunskega odziva, kar omogoči, da telo sprejme presajeni organ.
Advagraf reduces your body’s defence mechanism (immune system), which will not be as good at fighting infections.
Zdravilo Advagraf omeji vaše telesne obrambne mehanizme (imunski sistem), ki ne bodo tako dobri pri premagovanju okužb.
Advagraf therapy requires careful monitoring by adequately qualified and equipped personnel.
Zdravljenje z zdravilom Advagraf mora natančno nadzorovati ustrezno usposobljeno in opremljeno osebje.
Advanced Accelerator Applications Technopole de l’Aube 14 rue Gustave Eiffel 10430 Rosières près Troyes France
Advanced Accelerator Applications Technopole de l’Aube 14 rue Gustave Eiffel 10430 Rosières près Troyes Francija
Advanced Accelerator Applications – Saint Genis Pouilly 20 Rue Diesel
Advanced Accelerator Applications – Saint Genis-Pouilly 20 Rue Diesel
Advanced Accelerator Applications, 01630, Saint Genis Pouilly, France
Advanced Accelerator Applications, 01630, Saint Genis Pouilly, Francija
Advanced Accelerator Applications, 50100, Zaragoza, Spain
Advanced Accelerator Applications, 50100, Zaragoza, Španija
Advanced Accelerator Applications, 62660, Beuvry, France
Advanced Accelerator Applications, 62660, Beuvry, Francija
Advanced Accelerator Applications, Technopole de l’Aube,10430 Rosières près Troyes, France
Advanced Accelerator Applications, Technopole de l’Aube,10430 Rosières près Troyes, Francija
Advanced age, i.e. over 75 years
večja starost (več kot 75 let),
Advanced bleeding tendency
večjo nagnjenost h krvavitvam
Advanced breast cancer when certain other treatments (standard anthracycline-containing therapy) have been tried but have not worked or when the patient is unsuitable for these treatments.
napredovalega raka dojke, pri katerem so bile nekatere druge oblike zdravljenja (standardno zdravljenje z antraciklini) neuspešne, ali pri katerih tovrstno zdravljenje ni primerno
advanced cancer of the ovary (when the cancer has started to spread out of the ovary), in combination with cisplatin (another anticancer medicine);
napredovalega raka jajčnikov (ko se je rak začel širiti izven jajčnikov) v kombinaciji z zdravilom cisplatin (drugim zdravilom proti raku);
Advanced cirrhosis and post-liver transplant (ALLY-1)
Napredovala ciroza in stanje po presaditvi jeter (ALLY-1)
advanced gastric cancer (cancer of the stomach) or cancer of the area where the gullet (oesophagus) enters the stomach (known as gastro-oesophageal junction adenocarcinoma).
z napredovalim rakom želodca ali rakom predela, kjer požiralnik (ezofagus) vstopa v želodec (imenovanim adenokarcinom gastro-ezofagealnega prehoda).
Advanced glaucoma which cannot be adequately controlled by medicinal products alone.
Napredovani glavkom, ki ga ni mogoče zadostno nadzorovati samo z zdravili.
Advanced kidney disease
napredovalo bolezen ledvic
advanced melanoma (a type of skin cancer) in adults
napredovalega melanoma (vrsta kožnega raka) pri odraslih.
advanced melanoma, a type of skin cancer that has spread to other parts of the body or cannot be surgically removed.
napredovalim melanomom, vrsto kožnega raka, ki se je razširil na druge dele telesa ali ga ni mogoče kirurško odstraniti.
Advanced neuroendocrine tumours of gastrointestinal or lung origin
Napredovali nevroendokrini tumorji gastrointestinalnega ali pljučnega izvora
Advanced neuroendocrine tumours of pancreatic origin (pNET)
Napredovali nevroendokrini tumorji pankreatičnega izvora (pNET)
advanced non-small cell lung cancer (a type of lung cancer) in adults advanced renal cell carcinoma (advanced kidney cancer) in adults.
napredovalega nedrobnoceličnega pljučnega raka (vrsta pljučnega raka) pri odraslih. napredovalega karcinoma ledvičnih celic (napredovalega ledvičnega raka) pri odraslih.
Advanced non-small cell lung carcinoma
Napredovali nedrobnocelični karcinom plju:
Advanced ovarian cancer (first-line therapy)
Napredovali rak jajčnikov (zdravljenje prvega izbora)
Advanced ovarian cancer or remaining tumour (> 1 cm) after initial surgery, in combination with cisplatin as first-line treatment.
napredovalega karcinoma jajčnikov ali preostalega tumorja (> 1 cm) po začetni operaciji, v kombinaciji s cisplatinom kot zdravljenje prvega izbora
Advanced ovarian carcinoma (first-line treatment)
Napredovali karcinom jajčnikov (zdravljenje prvega izbora)
advanced renal cell carcinoma (a type of kidney cancer) when anticancer treatment with interferon alfa or interleukin 2 has failed or cannot be used; differentiated thyroid carcinoma (a type of cancer originating from the follicular cells of the thyroid gland) when the cancer has progressed or spread locally or to other parts of the body and does not respond to treatment with radioactive iodine.
napredovalim rakom ledvičnih celic (vrsto ledvičnega raka), če je bilo zdravljenje raka z interferonom alfa ali interlevkinom 2 neuspešno ali se ne more uporabiti; diferenciranim karcinomom ščitnice (vrsto raka, ki izvira iz folikularnih celic žleze ščitnice), kadar je rak napredoval ali se začel širiti lokalno ali v druge dele telesa in se ne odziva na zdravljenje z radioaktivnim jodom.
advanced renal cell carcinoma, a type of kidney cancer.
napredovalim karcinomom ledvičnih celic, vrsto raka ledvic.
Advanced renal impairment
napredovala okvara ledvic
ADVATE 1000 IU powder and solvent for solution for injection Octocog alfa
ADVATE 1000 i.e. prašek in vehikel za raztopino za injiciranje oktokog alfa
ADVATE 1000 IU powder and solvent for solution for injection Octocog alfa (recombinant human coagulation factor VIII)
ADVATE 1000 i.e. prašek in vehikel za raztopino za injiciranje oktokog alfa (rekombinantni humani koagulacijski faktor VIII)
ADVATE 1000 IU powder and solvent for solution for injection.
ADVATE 1000 i.e. prašek in vehikel za raztopino za injiciranje
ADVATE 1500 IU powder and solvent for solution for injection Octocog alfa
ADVATE 1500 i.e. prašek in vehikel za raztopino za injiciranje oktokog alfa
ADVATE 1500 IU powder and solvent for solution for injection Octocog alfa (recombinant human coagulation factor VIII)
ADVATE 1500 i.e. prašek in vehikel za raztopino za injiciranje oktokog alfa (rekombinantni humani koagulacijski faktor VIII)
ADVATE 1500 IU powder and solvent for solution for injection.
ADVATE 1500 i.e. prašek in vehikel za raztopino za injiciranje
ADVATE 2000 IU powder and solvent for solution for injection Octocog alfa
ADVATE 2000 i.e. prašek in vehikel za raztopino za injiciranje oktokog alfa
ADVATE 2000 IU powder and solvent for solution for injection Octocog alfa (recombinant human coagulation factor VIII)
ADVATE 2000 i.e. prašek in vehikel za raztopino za injiciranje oktokog alfa (rekombinantni humani koagulacijski faktor VIII)
ADVATE 2000 IU powder and solvent for solution for injection.
ADVATE 2000 i.e. prašek in vehikel za raztopino za injiciranje
ADVATE 250 IU powder and solvent for solution for injection ADVATE 500 IU powder and solvent for solution for injection ADVATE 1000 IU powder and solvent for solution for injection ADVATE 1500 IU powder and solvent for solution for injection
ADVATE 250 i.e. prašek in vehikel za raztopino za injiciranje ADVATE 500 i.e. prašek in vehikel za raztopino za injiciranje ADVATE 1000 i.e. prašek in vehikel za raztopino za injiciranje ADVATE 1500 i.e. prašek in vehikel za raztopino za injiciranje
ADVATE 250 IU powder and solvent for solution for injection Octocog alfa
ADVATE 250 i.e. prašek in vehikel za raztopino za injiciranje oktokog alfa
ADVATE 250 IU powder and solvent for solution for injection Octocog alfa (recombinant human coagulation factor VIII)
ADVATE 250 i.e. prašek in vehikel za raztopino za injiciranje oktokog alfa (rekombinantni humani koagulacijski faktor VIII)
ADVATE 250 IU powder and solvent for solution for injection.
ADVATE 250 i.e. prašek in vehikel za raztopino za injiciranje
ADVATE 3000 IU powder and solvent for solution for injection Octocog alfa
ADVATE 3000 i.e. prašek in vehikel za raztopino za injiciranje oktokog alfa
ADVATE 3000 IU powder and solvent for solution for injection Octocog alfa (recombinant human coagulation factor VIII)
ADVATE 3000 i.e. prašek in vehikel za raztopino za injiciranje oktokog alfa (rekombinantni humani koagulacijski faktor VIII)
ADVATE 3000 IU powder and solvent for solution for injection.
ADVATE 3000 i.e. prašek in vehikel za raztopino za injiciranje
ADVATE 500 IU powder and solvent for solution for injection Octocog alfa
ADVATE 500 i.e. prašek in vehikel za raztopino za injiciranje oktokog alfa
ADVATE 500 IU powder and solvent for solution for injection Octocog alfa (recombinant human coagulation factor VIII)
ADVATE 500 i.e. prašek in vehikel za raztopino za injiciranje oktokog alfa (rekombinantni humani koagulacijski faktor VIII)
ADVATE 500 IU powder and solvent for solution for injection.
ADVATE 500 i.e. prašek in vehikel za raztopino za injiciranje
Advate contains the active substance octocog alfa (human coagulation factor VIII).
Zdravilo vsebuje zdravilno učinkovino oktokog alfa (humani koagulacijski faktor VIII).
Advate given at high dose has been studied to see whether it is effective in clearing antibodies against factor VIII from the blood (a process known as immune tolerance induction) so that treatment with factor VIII remains effective.
Zdravilo Advate v visokem odmerku so preučevali, da bi ugotovili, ali je učinkovito pri odstranjevanju protiteles za faktor VIII iz krvi (proces, znan kot indukcija imunske tolerance), tako da zdravljenje s faktorjem VIII ostane učinkovito.
ADVATE has no influence on your ability to drive or to use machines.
Zdravilo ADVATE ne vpliva na sposobnost vožnje in upravljanja s stroji.
ADVATE in BAXJECT III system: Each pack contains a ready to use BAXJECT III system in a sealed blister (the powder vial and the vial containing 2 ml solvent are preassembled with the system for reconstitution).
Zdravilo ADVATE s sistemom BAXJECT III: Vsako pakiranje vsebuje pripravljen sistem BAXJECT III v zapečatenem pretisnem omotu (viala s praškom in viala s 2 ml vehikla, sestavljeni v sistemu za rekonstitucijo raztopine).
ADVATE in BAXJECT III system: Each pack contains a ready to use BAXJECT III system in a sealed blister (the powder vial and the vial containing 5 ml solvent are preassembled with the system for reconstitution).
Zdravilo ADVATE s sistemom BAXJECT III: Vsako pakiranje vsebuje pripravljen sistem BAXJECT III v zapečatenem pretisnem omotu (viala s praškom in viala s 5 ml vehikla, sestavljeni v sistemu za rekonstitucijo raztopine).
Advate is a powder and solvent that are mixed together to make a solution for injection.
Zdravilo Advate sestavljata prašek in vehikel, ki se zmešata v raztopino za injiciranje.
ADVATE is a white to off-white friable powder.
Zdravilo ADVATE je bel do belkast drobljiv prašek.
Advate is given by injection into a vein at a rate of up to 10 ml per minute.
Zdravilo Advate se daje z injiciranjem v veno s hitrostjo do 10 ml na minuto.
Advate is similar to another medicine approved in the European Union (EU) called Recombinate, but it is prepared differently so that there are no human- or animal-derived proteins in the medicine.
Zdravilo Advate je podobno drugemu zdravilu, ki je odobreno v Evropski uniji (EU), zdravilu Recombinate, vendar je pripravljeno na drugačen način, in sicer tako, da v njem ni nobenih beljakovin humanega ali živalskega izvora.
ADVATE is to be administered intravenously after reconstitution of the product.
Po rekonstituciji zdravila dajemo zdravilo ADVATE intravensko.
Advate is used for the treatment and prevention of bleeding in patients with haemophilia A (an inherited bleeding disorder caused by lack of factor VIII).
Zdravilo Advate se uporablja za zdravljenje in preprečevanje krvavitev pri bolnikih s hemofilijo A (prirojeno motnjo strjevanja krvi zaradi pomanjkanja faktorja VIII).
Advate is used to correct the factor VIII deficiency by replacing the missing factor VIII, giving temporary control of the bleeding disorder.
Z zdravilom Advate se popravi pomanjkanje faktorja VIII tako, da se nadomesti manjkajoči faktor VIII, kar vzpostavi začasni nadzor nad krvavitvami.
Advate must not be used in people who are hypersensitive (allergic) to human coagulation factor VIII, to mouse or hamster protein, or to any of the other ingredients.
Zdravila Advate ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) humani koagulacijski faktor VIII, na beljakovine miši ali hrčka ali katero koli drugo sestavino zdravila.
Advate should be started by a doctor who has experience in the treatment of haemophilia.
Zdravljenje z zdravilom Advate mora uvesti zdravnik, ki ima izkušnje z zdravljenjem hemofilije.
ADVATE with BAXJECT II device: Each pack contains a powder vial, a vial containing 2 ml solvent and a device for reconstitution (BAXJECT II).
Zdravilo ADVATE s pripomočkom BAXJECT II: Vsako pakiranje vsebuje vialo s praškom, vialo s 2 ml vehikla in pripomoček za rekonstitucijo raztopine (BAXJECT II).
ADVATE with BAXJECT II device: Each pack contains a powder vial, a vial containing 5 ml solvent and a device for reconstitution (BAXJECT II).
Zdravilo ADVATE s pripomočkom BAXJECT II: Vsako pakiranje vsebuje vialo s praškom, vialo s 5 ml vehikla in pripomoček za rekonstitucijo raztopine (BAXJECT II).
Adve rse re action
Neželeni učinek
Adverse central nervous system reactions observed in patients treated with asparaginase-containing therapy protocols include changes in EEG, seizures, dizziness, somnolence, coma and headache.
Neželeni učinki na centralno živčevje, ki so jih opazili pri bolnikih, zdravljenih s terapevtskimi protokoli, ki vsebujejo asparaginazo, vključujejo spremembe EEG, epileptične napade, omedlevico, somnolenco, komo in glavobol.
Adverse Drug Reaction
Neželena reakcija na zdravilo
Adverse Drug Reaction
Neželeni učinek
Adverse Drug Reaction
Neželeni učinek na zdravilo
Adverse Drug Reaction
Neželeni učinek zdravila
Adverse Drug Reaction (ADR)
Neželeni učinek zdravila
Adverse drug reaction reported post-marketing only (i.e. not in clinical trials) are presented with a frequency of not known.
Neželeni učinki, ki so bili opisani po začetku trženja (tj. ne v kliničnih preskušanjih), so navedeni s pogostnostjo "neznano".
Adverse Drug Reactions
Neţelene reakcije na zdravilo
Adverse drug reactions
Neželeni učinki
Adverse drug reactions (ADR) reported with Pixuvri are from final data from all completed studies.
Neželeni učinki zdravila, o katerih so poročali pri uporabi zdravila Pixuvri, temeljijo na končnih podatkih vseh dokončanih študij.
Adverse Drug Reactions (ADRs) which were reported in patients with advanced gastric cancer, mCRC or NSCLC are listed below by MedDRA body system organ class, frequency and grade of severity.
Neželeni učinki zdravila, o katerih so poročali pri bolnikih z napredovalim rakom želodca, metastatskim kolorektalnim rakom ali nedrobnoceličnim pljučnim rakom so navedeni spodaj po organskih sistemih, pogostnosti in resnosti glede na podatkovno bazo MedDRA.
Adverse drug reactions (ADRs) which were reported in patients with squamous non-small cell lung cancer are listed below in MedDRA body system organ class, frequency and grade of severity.
Neželeni učinki zdravila, o katerih so poročali pri bolnikih s skvamoznim nedrobnoceličnim pljučnim rakom, so navedeni spodaj po organskih sistemih, pogostnosti in resnosti glede na podatkovno bazo MedDRA.
Adverse drug reactions are listed according to system organ class (SOC) in MedDRA.
Neželeni učinki so navedeni po organskih sistemih (SOC – system organ class) MedDRA.
Adverse drug reactions during clinical trials
Neželeni učinki zdravila med kliničnimi preskušanji
Adverse drug reactions following the use of Econor are mainly associated with breeds and cross breeds of Danish and/or Swedish Landrace.
Neželeni učinki po uporabi zdravila Econor so največkrat vidni pri prašičih pasme danski in/ali švedski landrace ter njihovih križancih.
Adverse drug reactions for both treatments, dabigatran etexilate and warfarin, are counted from the first intake of dabigatran etexilate or warfarin after the parenteral therapy has been discontinued (oral only treatment period).
Podatke o neželenih učinkih na obe zdravili, dabigatran eteksilat in varfarin, so začeli zbirati pri prvi uporabi dabigatran eteksilata ali varfarina po ukinitvi parenteralnega zdravljenja (obdobje zdravljenja, ko so bolniki jemali samo peroralna zdravila).
Adverse drug reactions from post-marketing surveillance as spontaneously reported during a period in which an estimated >70 million patients were treated with celecoxib (various doses, durations, and indications).
Neželeni učinki zdravila med pomarketinškim spremljanjem, spontano prijavljeni v obdobju, med katerim je celekoksib po ocenah dobivalo > 70 milijonov bolnikov (različni odmerki, trajanje in indikacije).
Adverse drug reactions identified as those with a ≥ 1% incidence, similar or higher incidence in the BR- CAP arm and with at least a possible or probable causal relationship to the components of the BR-CAP arm, are listed in Table 8 below.
V preglednici 8 so navedeni ugotovljeni neželeni učinki s pogostnostjo ≥ 1%, ki je bila podobna ali večja v skupini BR-CAP in z najmanj verjetno ali možno vzročno povezanostjo s komponentami v skupini BzR-CAP.
Adverse drug reactions identified during clinical trials and post-marketing experience with Doribax
Neželeni učinki zdravila, ugotovljeni med kliničnimi preskušanji in postmarketinško uporabo zdravila Doribax
Adverse drug reactions identified during the post-marketing experience with Caelyx
Neželeni učinki ugotovljeni v obdobju trženja zdravila Caelyx
Adverse Drug Reactions in Female Partners
Neželeni učinki zdravila pri partnerkah
Adverse Drug Reactions in Male Glans-penis-treated Subjects
Neželeni učinki zdravila pri moških preiskovancih, ki so prejemali zdravljenje glavice penisa
Adverse drug reactions listed for the post-marketing population are only those that are not already listed for the arthritis trials (Table 1)
Za pomarketinško populacijo so navedeni le tisti neželeni učinki zdravila, ki niso navedeni že za preskušanja pri artritisu (preglednica 1) ali za preskušanja pri preprečevanju polipov (preglednica 2).
Adverse drug reactions listed for the post-marketing population are only those that are not already listed for the arthritis trials (Table 1) or the polyp prevention trials (Table 2).
Za pomarketinško populacijo so navedeni le tisti neželeni učinki zdravila, ki niso navedeni že za preskušanja pri artritisu (preglednica 1) ali za preskušanja pri preprečevanju polipov (preglednica 2).
Adverse drug reactions reported in AURAa studies
Neželeni učinki, zabeleženi v študijah AURAa
Adverse Drug Reactions Reported in Clinical Trials and Postmarketing Experience
Neželeni učinki o katerih so poročali v kliničnih preskušanjih in v redni klinični praksi
Adverse drug reactions reported related to Pixuvri in completed Pixuvri studies by frequency
Neželeni učinki zdravila, o katerih so poročali v povezavi z zdravilom Pixuvri v dokončanih študijah z zdravilom Pixuvri, razvrščeni po pogostnosti
Adverse Drug Reactions Reported with Intuniv
Neželeni učinki, o katerih poročajo pri zdravilu Intuniv
Adverse drug reactions such as nausea, vomiting, diarrhoea and sweating were reported.
Poročajo o neželenih učinkih, kot so slabost, bruhanje, driska in znojenje.
Adverse drug reactions such as somnolence and vertigo have been reported in INTELENCE treated subjects at incidences similar to placebo (see section 4.8).
Pojavnost neželenih učinkov kot sta somnolenca in vrtoglavica je bila pri preiskovancih, ki so jih zdravili z zdravilom INTELENCE, podobna kot pri placebu (glejte poglavje 4.8).
Adverse Drug Reactions, from clinical trials and spontaneous reports
Neželeni učinki iz kliničnih preskušanj in spontanih poročil
Adverse effects of ibandronic acid in reproductive toxicity studies in the rat were those observed with bisphosphonates as a class.
Neželeni učinki ibandronske kisline v študijah vpliva na sposobnost za razmnoževanje pri podganah so bili značilni za to skupino zdravil (difosfonati).
Adverse effects of ibandronic acid in reproductive toxicity studies in the rat were those observed with bisphosphonates as a class.
Neželeni učinki ibandronske kisline v študijah vplivov na sposobnost razmnoževanja pri podganah so bili pričakovano značilni za to vrsto zdravil (difosfonati).
Adverse event
Neželeni učinek
Adverse event reactions for bivalirudin are listed by system organ class in Table 1.
Neželeni učinki bivalirudina so našteti po organskih sistemih v preglednici 1.
Adverse event reporting forms
Obrazci za poročanje neželenih učinkov
Adverse events
Neželeni dogodki
Adverse Events
Neželeni učinek
Adverse events applicable to all indications:
Neželeni učinki, ki se pojavljajo pri vseh indikacijah:
Adverse events include verbatim terms in parentheses.
V oklepajih so navedbe za neželene učinke z nestrokovnimi izrazi.
Adverse Events leading to discontinuation occurred at a similar frequency in both treatment groups (riociguat individual dose titration (IDT) 1.0-2.5 mg, 2.9%; placebo, 2.3%).
Neželeni učinki, ki so privedli do prenehanja zdravljenja, so se v obeh zdravljenih skupinah pojavljali s podobno pogostnostjo (titriranje odmerka riociguata za posameznega bolnika (IDT - individual dose titration) 1,0 – 2,5 mg, 2,9 %; placebo 2,3 %).
Adverse events of liver abnormalities and anaemia/haemoglobin decrease occurred in 9% and 5% of patients, respectively.
Neželeni učinki v obliki nenormalnih jetrnih testov in anemije /znižane vrednosti hemoglobina so se pojavili pri 9 % oziroma 5 % bolnikov.
Adverse events of nausea,
ritonavirja so kot neželene učinke
Adverse events of nausea, dizziness,
Zdravila po terapevtskih
Adverse events of nausea, dizziness, hypotension and syncope have been observed following co- administration of trazodone and ritonavir in this study.
V tej raziskavi so po sočasnem jemanju trazodona in ritonavirja opazili neželene učinke, kot so slabost,
Adverse events of nausea, dizziness, hypotension and syncope have been observed following co- administration of trazodone and ritonavir in this study.
V tej raziskavi so po sočasnem jemanju trazodona in ritonavirja opazili neželene učinke, kot so slabost, omotica, hipotenzija in sinkopa.
Adverse Events of Special Interest (PTs)
Neželeni učinki posebnega pomena (PT)
Adverse Events of Special Interest stratified according to type of report (medically confirmed or non-medically confirmed).
Neželeni učinki posebnega pomena (Adverse Events of Special Interest – AESI), razvrščeni v razrede po vrsti poročila (medicinsko ali nemedicinsko potrjenega).
Adverse events of the haematologic system, including medically significant cytopoenia (e.g. thrombocytopaenia, leucopaenia) have been reported with Humira.
Med uporabo zdravila Humira so poročali o neželenih učinkih na hematološki sistem, vključno z medicinsko pomembno citopenijo (npr. trombocitopenijo, levkopenijo).